Bayley Matthew D 4
4 · Aevi Genomic Medicine, Inc. · Filed Feb 5, 2020
Insider Transaction Report
Form 4
Bayley Matthew D
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Purchase)
2020-02-03−50,000→ 0 totalExercise: $1.55Exp: 2028-04-17→ Common Stock (50,000 underlying) - Disposition to Issuer
Stock Option (Right to Purchase)
2020-02-03−40,000→ 0 totalExercise: $1.25Exp: 2027-12-04→ Common Stock (40,000 underlying)
Footnotes (2)
- [F1]This option, which became exercisable on December 4, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger").
- [F2]This option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.